Seoulin BioscienceLtd Balance Sheet Health
Financial Health criteria checks 5/6
Seoulin BioscienceLtd has a total shareholder equity of ₩84.9B and total debt of ₩1.5B, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are ₩97.8B and ₩12.9B respectively. Seoulin BioscienceLtd's EBIT is ₩737.1M making its interest coverage ratio -1.6. It has cash and short-term investments of ₩24.8B.
Key information
1.7%
Debt to equity ratio
₩1.46b
Debt
| Interest coverage ratio | -1.6x |
| Cash | ₩24.81b |
| Equity | ₩84.88b |
| Total liabilities | ₩12.91b |
| Total assets | ₩97.79b |
Recent financial health updates
No updates
Recent updates
Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For Excitement
Dec 04
Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's Why
May 03Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 13Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last Year
Feb 15Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?
Jan 20
Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-Dividend
Dec 25Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Dec 06Financial Position Analysis
Short Term Liabilities: A038070's short term assets (₩57.2B) exceed its short term liabilities (₩11.5B).
Long Term Liabilities: A038070's short term assets (₩57.2B) exceed its long term liabilities (₩1.4B).
Debt to Equity History and Analysis
Debt Level: A038070 has more cash than its total debt.
Reducing Debt: A038070's debt to equity ratio has increased from 0.2% to 1.7% over the past 5 years.
Debt Coverage: A038070's debt is well covered by operating cash flow (99.3%).
Interest Coverage: A038070 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 06:55 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Seoulin Bioscience Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Ju-Hong Choe | LS Securities Co., Ltd. |
| Seung Kim | SK Securities Co., Ltd. |